Fiammetta Vanoli

Dr. Fiammetta Vanoli

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2018 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
EBElisabetta Bucci
Elisabetta Bucci
MTMarco Testa
Marco Testa
LLLoretta Licchelli
Loretta Licchelli
AFAlessandra Frattari
Alessandra Frattari
NHNadia Attalla El Halabieh
Nadia Attalla El Halabieh
GAGiovanni Antonini
Giovanni Antonini

9 June 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
NINicola Iacomino
Nicola Iacomino
FVFiammetta Vanoli
Fiammetta Vanoli
RFRita Frangiamore
Rita Frangiamore
MBMarta Ballardini
Marta Ballardini
LSLetizia Scandiffio
Letizia Scandiffio
Renato MantegazzaRenato Mantegazza
Renato Mantegazza
The complement system plays a key role in myasthenia gravis (MG). Anti-complement drugs are emerging as effective therapies to treat anti-acetylcholine receptor (AChR) antibody-positive MG patients, though their usage is still limited by the high costs. Here, we searched for plasma complement proteins as indicators of complement activation status in AChR-MG patients, and potential biomarkers for tailoring anti-complement therapy in MG. Plasma was collected from AChR-MG and MuSK-MG patients, and healthy controls. Multiplex immunoassays and ELISA were used to quantify a panel of complement components (C1Q, C2, C3, C4, C5, Factor B, Factor H, MBL, and properdin) and activation products (C4b, C3b, C5a, and C5b-9), of classical, alternative and lectin pathways. C2 and C5 levels were significantly reduced, and C3, C3b, and C5a increased, in plasma of AChR-MG, but not MuSK-MG, patients compared to controls. This protein profile was indicative of complement activation. We obtained sensitivity and specificity performance results suggesting plasma C2, C3, C3b, and C5 as biomarkers for AChR-MG. Our findings reveal a plasma complement “C2, C3, C5, C3b, and C5a” profile associated with AChR-MG to be further investigated as a biomarker of complement activation status in AChR-MG patients, opening new perspectives for tailoring of anti-complement therapies to improve the disease treatment.

24 October 2023 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
RFRita Frangiamore
Rita Frangiamore
ERElena Rinaldi
Elena Rinaldi
FVFiammetta Vanoli
Fiammetta Vanoli
FAFrancesca Andreetta
Francesca Andreetta
Renato MantegazzaRenato Mantegazza
Renato Mantegazza
CACarlo Antozzi
Carlo Antozzi

25 March 2025 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
CACarlo Antozzi
Carlo Antozzi
RFRita Frangiamore
Rita Frangiamore
ERElena Rinaldi
Elena Rinaldi
FVFiammetta Vanoli
Fiammetta Vanoli
FAFrancesca Andreetta
Francesca Andreetta
Renato MantegazzaRenato Mantegazza
Renato Mantegazza

1 January 2020 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
LLLuca Leonardi
Luca Leonardi
SLSimona Loreti
Simona Loreti
APAntonella Di Pasquale
Antonella Di Pasquale
SMStefania Morino
Stefania Morino
LFLaura Fionda
Laura Fionda
GAGiovanni Antonini
Giovanni Antonini

19 June 2025 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SDSarah Dewilde
Sarah Dewilde
NTNafthali H. Tollenaar
Nafthali H. Tollenaar
PBPierre Boulanger
Pierre Boulanger
AAAnnie Archer
Annie Archer
RPRaquel Pardo
Raquel Pardo
SPSandra Paci
Sandra Paci
Introduction/aims: Informal caregivers play an important role in the lives of people with Myasthenia gravis (MG). This study aims to assess the caregiver burden (CB) experienced by caregivers of MG patients. Methods: A cross-sectional study design collected patient and caregiver data in Germany, Italy, Spain, the UK, and France. The Zarit Burden Interview (ZBI-22), EQ-5D-5L and bolt-on questions, and PROMIS Global Health-10 were used to measure CB and overall health-related quality of life (HRQoL). Results: Caregivers (N = 69) reported a mean ZBI-22 score of 24.3, with 40.6% reporting no burden, 47.8% mild-to-moderate burden, 8.7% moderate-to-severe burden, and 2.9% severe burden. The most impacted ZBI-22 dimensions were “losing control over one’s life”, “financial burden” and “relationships with relatives”. Based on a generic health-related quality of life scale (EQ-5D-5L plus bolt-on questions), the dimensions that were more frequently reported among MG caregivers to cause moderate-to-extreme problems were: tiredness (43%), self-confidence (32%), and anxiety/depression (28%). EQ-5D-5L utilities (values from -1 to 1, reflecting overall HRQoL) were negatively associated with higher ZBI-22 scores (little or no burden: 0.942, mild-to-moderate burden: 0.864, moderate-to-severe burden: 0.783, severe burden: 0.570). Regarding PROMIS-10 items, 48% of caregivers reported often/always being bothered by anxiety, depression, or irritation; 47% reported being not at all or little able to carry out daily activities; and 37% reported having (very) severe fatigue. Conclusion: Informal caregivers of MG patients experience a substantial burden, impacting their physical, emotional, and financial well-being. Findings highlight the need for tailored interventions to alleviate CB and enhance the caregivers’ overall HRQoL.